COLOSSUS ( partner HalioDx SAS, an immuno-oncology diagnostic company headquartered in Marseille, France, recently announced that their diagnostic test Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer.

Immunoscore® was considered for its ability to refine the prognosis for people in the early stages of colon cancer, in conjunction with the TNM scoring. As such, this combination of tests has led to the adjustment of the chemotherapy decision-making process for people with stage II and in low-risk stage III cancer of the colon.

In addition to this impressive achievement, HalioDx has entered into a Collaboration Agreement with the FFCD, the French Cooperative Group dedicated exclusively to digestive oncologyon the Phase II multi-center POCHI trial (FFCD1703 – NCT04262687) in which immune response at the tumour site will be used to inform patient eligibility to participate in the POCHI trial. The aim of this trial is to evaluate the efficacy of pembrolizumab in combination with XELOX (capecitabine plus oxaliplatin) and bevacizumab as first-line treatment of microsatellite stable (MSS)/proficient mismatch repair system (pMMR) metastatic colorectal cancer (mCRC) with high immune infiltrate. Read the press release here.

Within COLOSSUS, HalioDx works with a team to complete the biorepository and histopathology analyses. In addition, they work to develop a customized Next Generation Sequencing (NGS) companion diagnostic test. Once established, the COLOSSUS classifiers will be translated into a targeted NGS assay to enable fast and efficient determination of the COLOSSUS clusters.

Watch a short video to learn more about the COLOSSUS project and the ongoing clinical study:

  COLOSSUS has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 754923. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.